EMA Authorised: HyQvia (human normal immunoglobulin) — Baxalta Innovations GmbH

View source ↗

Summary

The EMA has authorised HyQvia (human normal immunoglobulin) from Baxalta Innovations GmbH for use in immunologic deficiency syndromes and related neuropathies, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunologic Deficiency Syndromes
• Polyradiculoneuropathy
• Polyradiculoneuropathy Chronic Inflammatory Demyelinating

Drugs mentioned

• HYQVIA (immunoglobulin G (IgG) with recombinant human hyaluronidase)

Snippet

Status: Authorised. Therapeutic area: Immunologic Deficiency Syndromes;Polyradiculoneuropathy;Polyradiculoneuropathy, Chronic Inflammatory Demyelinating. MAH: Baxalta Innovations GmbH. Decision date: 03/04/2025